PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines-Reference-Cited by-同舟云学术

PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines

Published:2021-06 Issue: Volume:138 Page:111436
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Lotfinejad Parisa,Kazemi Tohid,Safaei Sahar,Amini Mohammad,Roshani asl Elmira,Baghbani Elham,Sandoghchian Shotorbani Siamak,Jadidi Niaragh Farhad,Derakhshani Afshin,Abdoli Shadbad Mahdi,Silvestris Nicola,Baradaran Behzad

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference58 articles.

1. Abstract 4191: the worldwide female breast cancer incidence and survival, 2018;Zaidi;Cancer Res.,2019

2. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups;Curtis;Nature,2012

3. Characteristics of triple-negative breast cancer;de Ruijter;J. Cancer Res. Clin. Oncol.,2011

4. Triple-negative breast cancer: the progress of targeted therapies and future tendencies;Damaskos;Anticancer Res.,2019

5. Immune checkpoint receptors in regulating immune reactivity in rheumatic disease;Ceeraz;Arthritis Res. Ther.,2014

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PGM5-AS1 Promotes Progression of Diffuse Large B-Cell Lymphoma and Immune Escape by Regulating miR-503-5p;Journal of Inflammation Research;2024-07

2. Bioinformatic analysis and experimental validation of six cuproptosis-associated genes as a prognostic signature of breast cancer;PeerJ;2024-06-18

3. PD-L1 intrinsically promotes the proliferation of breast cancer cells through the SKP2-p27/p21 axis;Cancer Cell International;2024-05-09

4. Sophora flavescens-Angelica sinensis in the treatment of eczema by inhibiting TLR4/MyD88/NF-κB pathway;Journal of Ethnopharmacology;2024-03

5. Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer;Biomedicines;2024-02-05